Arena Pharmaceuticals Inc. (ARNA) said it expanded its marketing agreement with Eisai (4523) Co. for the diet drug Belviq and received an upfront payment of $60 million. Eisai, based in Tokyo, will now market the product in all countries except South Korea, Taiwan, Australia, Israel, and New Zealand, San Diego-based Arena said today in statement. The two companies received approval from the Food and Drug Administration in June 2012 to market the diet pill in the U.S. and clearance from the Drug Enforcement Agency to start sales in May.
Help employers find you! Check out all the jobs and post your resume.
